Next Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Speaker bio
- Content
- Part 1 (Intro)
- Portfolio management in pharmaceutical R&D
- Portfolio management in the pharma industry
- Best practice portfolio management in big pharma
- Evaluation of individual projects
- The five determinants of value
- Net Present Value (NPV) equation
- Financial project evaluation
- Sources of risk
- How to calculate NPVs
- Attrition rates & reasons for failure in R&D
- R&D risk management
- Commercial risks
- Sales forecast (15 trials in Monte Carlo simulation)
- Monte Carlo simulation: frequency histogram
- Added value per completed milestone
- Getting to valid assumptions and good decisions
Topics Covered
- Portfolio management in pharmaceutical R&D and industry
- Best practice portfolio management in big pharma
- Evaluation of individual projects
- The five determinants of value
- Net Present Value (NPV) equation
- Financial project evaluation
- Sources of risk
- How to calculate NPVs
- Attrition rates & reasons for failure in R&D
- R&D risk management
- Commercial risks
- Sales forecast (15 trials in Monte Carlo simulation)
- Monte Carlo simulation: frequency histogram
- Added value per completed milestone
- Getting to valid assumptions and good decisions
Talk Citation
Greuel, J.M. (2025, March 11). Portfolio planning and risk management in the pharmaceutical industry 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 12, 2025, from https://doi.org/10.69645/YABM3559.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Joachim M. Greuel has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Portfolio planning and risk management in the pharmaceutical industry 1
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
I am Joachim Greuel,
Managing Director at Bioscience Valuation,
a company engaged in portfolio management
and risk management as well.
And I'm going to talk about
Portfolio Planning
and Risk Management
in the Pharmaceutical Industry.
0:21
Before I begin, a few words about myself,
I studied biology in Germany and in the UK,
and received a PhD in neuroscience
from the Max-Planck-Institute
for Brain Research.
I also hold an MBA
from the Wharton School of the University
of Pennsylvania in the US
with a healthcare management
and finance focus.
I also served as academic director
and professor
at the IE Business School in Madrid,
teaching courses related to pharmacoeconomics
and also related to portfolio managements
in the pharmaceutical industry.
Before I co-founded Bioscience Valuation
more than 18 years ago,
I worked for Bayer Pharmaceuticals
as head of a research group
for couple of years
and also as investment manager
for a venture capital fund in Switzerland.
1:21
The presentation is divided into four parts.
I will start with a short introduction
and then move on to the evaluation
of individual projects.
The evaluation of individual projects
is a prerequisite for portfolio management.
The third part will talk about
portfolio planning and risk management,
and the final section will focus on project
and portfolio value maximization.
Hide